Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: A series of 21 BM or PBSC transplant patients

Bone Marrow Transplantation

Volumn 30, Issue 5, 2002, Pages 287-295

  Baudard, M ^a   Vincent, A ^a   Moreau, P ^a   Kergueris, M F ^a   Harousseau, J L ^a   Milpied, N ^a  

^a HÔTEL DIEU   (France)

Author keywords

Graft versus host disease; Mycophenolate mofetil; Stem cell transplantation

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; LYMPHOCYTE ANTIBODY; METHOTREXATE; PENICILLIN G; PENTAMIDINE; ROXITHROMYCIN; STEROID; THALIDOMIDE;

ACUTE DISEASE; ADULT; ARTICLE; BIOTRANSFORMATION; BONE MARROW TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DRUG SCREENING; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; OPPORTUNISTIC INFECTION; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY; RISK; TREATMENT OUTCOME; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DONOR; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; ENTEROPATHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; INFECTION; INFECTION RISK; LEUKEMIA; LICHENOID; LIVER DISEASE; LYMPHOMA; MULTIPLE MYELOMA; MYELOFIBROSIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SCLERODERMA; SKIN DISEASE; TREATMENT FAILURE; VIRUS INFECTION;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTRANSFORMATION; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DRUG EVALUATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; OPPORTUNISTIC INFECTIONS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 0036740742     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703633     Document Type: Article

References (36)

1. Kiehl MG, Shipkova M, Basara N et al. New strategies in GVHD prophylaxis. Bone Marrow Transplant 2000; 25 (Suppl. 2): S16-S19.
2. Byrne JL, Stainer C, Hyde H et al. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant 1998; 22: 541-545.
3. Zikos P, Van Lint MT, Frassoni F et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91: 3503-3508.
4. Michallet M, Perrin MC, Belhabri A et al. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 145-150.
5. Deeg HJ, Lin D, Leisenring W et al. Cyor cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997; 89: 3880-3887.
6. Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
7. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
8. Nash RA, Pineiro LA, Storb R et al. FK506 in combination with methotrexate for the prevention of graft-versus-host-disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634-3641.
9. Deeg HJ. Prophylaxis and treatment of acute graft-versus-host-disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high risk patients. Bone Marrow Transplant 1994; 14 (Suppl. 4): S56-S60.
10. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host-disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood 1995; 86: 1228-1234.
11. Storb R, Pepe M, Anasetti C et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037-1045.
12. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 1988; 72: 555-561.
13. Schiller G, Gale RP. Is there an effective therapy for chronic graft-versus-host disease? Bone Marrow Transplant 1993; 11: 189-192.
14. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517-520.
15. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196-1201.
16. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77-84.
17. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-243.
18. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39-47 (erratum, Transplantation 1997; 63: 618).
19. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1157-1162.
20. Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-504.
21. Basara N, Blau WI, Kiehl E et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 2000; 14: 121-126.
22. Basara N, Blau WI, Kiehl E et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipients. Transplant Proc 1998; 30: 4087-4089.
23. Przepiorka D, Weisdorf D, Martin P et al. Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
24. Busca A, Saroglia E, Lanino E et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000; 25: 1067-1071.
25. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Oxford, 1994, pp 339-362.
26. Tsina I, Kaloostian M, Lee R et al. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma. J Chromatogr B 1996; 681: 347-353.
27. Sugioka N, Odani H, Ohta T et al. Determination of a new immunosuppressant, mycophenolate mofetil, and its active metabolite, mycophenolic acid, in rat and human body fluids by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994; 654: 249-256.
28. Torgovnick J, Arsura EL, Lala D. Cytomegalovirus ventriculoencephalitis presenting as a Wernicke's encephalopathy-like syndrome. Neurology 2000; 55: 1910-1913.
29. Weber LT, Shipkova M, Lamersdorf T et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1988; 9: 1511-1520.
30. Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic bone marrow transplantation. Blood 1988; 72: 546-554.
31. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000; 15: 711-714.
32. Sarmiento JM, Dockrell DH, Schwab TR et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14: 136-138.
33. Kiehl MG, Shipkova M, Basara N et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem 2000; 33: 203-208.
34. Shaw LM, Holt DW, Keown P et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 21: 1632-1652.
35. Mourad M, Malaise J, Chaib Eddour D et al. Correlation of mycophenolic acid pharmacokinetic parameters with side-effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 88-94.
36. Bullingham R, Nicholls A, Kamm B. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.